Baxter Cardiovascular Business To Boost R&D Spending After Spin-Off
This article was originally published in The Gray Sheet
Executive Summary
The soon-to-be independent Baxter Cardiovascular Group's R&D spending is expected to increase by 50% over the current coporate rate of 6%.